Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Breast cancer is a heterogeneous disease with diverse molecular subtypes, leading to significant mortality due to metastasis and recurrence.
• Precision medicine aims to minimize chemotherapeutic toxicities and maximize patient benefits through targeted therapies.
• Advancements in omics technologies and next-generation sequencing are driving more precise treatment strategies.

Purpose of the Study:

• To review recent advancements in precision medicine for treating metastatic breast cancer and triple-negative breast cancer (TNBC).
• To highlight the role of biomarkers in guiding targeted therapy selection for specific patient groups.
• To discuss emerging targeted therapies and their potential in BC and TNBC treatment.

Main Methods:

• Review of current literature on precision medicine in breast cancer.
• Analysis of omics technologies and next-generation sequencing applications.
• Identification and categorization of various targeted therapy approaches.

Main Results:

• Several druggable mutations have been identified in breast cancer patients.
• Next-generation sequencing facilitates precision medicine strategies for BC and TNBC.
• Targeted therapies including immune checkpoint inhibitors, EGFR inhibitors, PARP inhibitors, ADCs, and oncolytic viruses show promise.

Conclusions:

• Precision medicine is essential for effective breast cancer treatment and prevention.
• Targeted therapies offer promising avenues for managing metastatic and TNBC.
• Continued research in omics and sequencing technologies will further refine precision oncology approaches.